Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IBB NASDAQ:REGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBBiShares Biotechnology ETF$151.32+0.3%$141.61$107.43▼$153.01$6.32B0.842.22 million shs1.64 million shsREGNRegeneron Pharmaceuticals$572.60+2.7%$573.72$476.49▼$1,024.36$59.11B0.311.21 million shs1.01 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBBiShares Biotechnology ETF+0.25%+0.56%+7.33%+15.35%+3.85%REGNRegeneron Pharmaceuticals+2.67%-1.82%+2.25%+4.50%-43.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBBiShares Biotechnology ETF$151.32+0.3%$141.61$107.43▼$153.01$6.32B0.842.22 million shs1.64 million shsREGNRegeneron Pharmaceuticals$572.60+2.7%$573.72$476.49▼$1,024.36$59.11B0.311.21 million shs1.01 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBBiShares Biotechnology ETF+0.25%+0.56%+7.33%+15.35%+3.85%REGNRegeneron Pharmaceuticals+2.67%-1.82%+2.25%+4.50%-43.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBBiShares Biotechnology ETF 2.66Moderate Buy$151.32N/AREGNRegeneron Pharmaceuticals 2.79Moderate Buy$817.8842.84% UpsideCurrent Analyst Ratings BreakdownLatest REGN and IBB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025REGNRegeneron PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$850.0010/13/2025REGNRegeneron PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$650.00 ➝ $660.0010/10/2025REGNRegeneron PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$761.00 ➝ $756.0010/8/2025REGNRegeneron PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025REGNRegeneron PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/2/2025REGNRegeneron PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy8/27/2025REGNRegeneron PharmaceuticalsSanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$753.00 ➝ $781.008/27/2025REGNRegeneron PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$813.00 ➝ $831.008/14/2025REGNRegeneron PharmaceuticalsRedburn AtlanticSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/14/2025REGNRegeneron PharmaceuticalsRothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$890.00(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBBiShares Biotechnology ETFN/AN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$14.21B4.27$46.93 per share12.20$268.50 per share2.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBBiShares Biotechnology ETFN/AN/A0.00∞N/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$4.41B$39.6814.4315.061.7831.37%15.06%11.77%10/28/2025 (Estimated)Latest REGN and IBB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/28/2025Q3 2025REGNRegeneron Pharmaceuticals$9.73N/AN/AN/A$3.57 billionN/A8/1/2025Q2 2025REGNRegeneron Pharmaceuticals$8.43$12.89+$4.46$12.81$3.30 billion$3.68 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIBBiShares Biotechnology ETF$0.260.17%N/AN/AN/AREGNRegeneron Pharmaceuticals$3.520.61%N/A8.87%N/ALatest REGN and IBB DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date9/15/2025IBBiShares Biotechnology ETFquarterly$0.08280.24%9/16/20259/16/20259/19/20258/1/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.6%8/18/20258/18/20259/3/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBBiShares Biotechnology ETFN/AN/AN/AREGNRegeneron Pharmaceuticals0.094.603.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBBiShares Biotechnology ETF62.45%REGNRegeneron Pharmaceuticals83.31%Insider OwnershipCompanyInsider OwnershipIBBiShares Biotechnology ETFN/AREGNRegeneron Pharmaceuticals7.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBBiShares Biotechnology ETFN/A41.75 millionN/AOptionableREGNRegeneron Pharmaceuticals15,106105.99 million98.55 millionOptionableREGN and IBB HeadlinesRecent News About These CompaniesUS Bancorp DE Sells 858 Shares of Regeneron Pharmaceuticals, Inc. $REGN2 hours ago | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of "Moderate Buy" by Analysts2 hours ago | americanbankingnews.comCanaccord Genuity Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation2 hours ago | msn.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of "Moderate Buy" from Analysts3 hours ago | marketbeat.comCitigroup Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock2 hours ago | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down After Analyst Downgrade3 hours ago | americanbankingnews.comRegeneron Pharmaceuticals Shapes Nasdaq Futures with Market ImpactOctober 14 at 4:43 PM | kalkinemedia.comKRegeneron’s Q3 2025 Earnings: What to ExpectOctober 14 at 4:43 PM | msn.comRegeneron Pharmaceuticals (NASDAQ:REGN) Receives Buy Rating from Canaccord Genuity GroupOctober 14 at 10:25 AM | marketbeat.comMorningstar Investment Management LLC Makes New $608,000 Investment in Regeneron Pharmaceuticals, Inc. $REGNOctober 14 at 7:05 AM | marketbeat.comHudson Capital Management LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGNOctober 14 at 5:55 AM | marketbeat.comVanguard Personalized Indexing Management LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. $REGNOctober 14 at 4:24 AM | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Citigroup Analyst SaysOctober 13 at 12:21 PM | marketbeat.comRegeneron plans FDA filing based on latest DB-OTO dataOctober 13 at 11:45 AM | thepharmaletter.comTREGN Reports Encouraging Data on Gene Therapy for Genetic Hearing LossOctober 13 at 11:06 AM | zacks.comRegeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M ChargeOctober 13 at 10:51 AM | insidermonkey.comRegeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down on Analyst DowngradeOctober 13 at 10:40 AM | marketbeat.comCwm LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGNOctober 13 at 6:30 AM | marketbeat.comMorgan Stanley Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $756.00October 13 at 2:27 AM | americanbankingnews.comCantor Fitzgerald Brokers Raise Earnings Estimates for REGNOctober 13 at 2:52 AM | marketbeat.comRegeneron Pharmaceuticals Reports Positive Phase 1/2 Results for DB-OTO Gene Therapy in Treating Profound OTOF-Related Hearing LossOctober 12 at 10:30 AM | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeREGN and IBB Company DescriptionsiShares Biotechnology ETF NASDAQ:IBB$151.32 +0.38 (+0.25%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$150.89 -0.43 (-0.28%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.Regeneron Pharmaceuticals NASDAQ:REGN$572.60 +14.87 (+2.67%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$568.29 -4.31 (-0.75%) As of 04:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Healthcare Companies Insiders Are Buying NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
